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Abstract 33 
Squamous cell carcinoma of the vulva is predominantly a disease of the elderly, where the mainstay 34 
of treatment is radical surgery. Local vulval recurrence (LVR) is a significant problem for these 35 
patients, and the rates of recurrence have not improved over the last three decades. Disappointingly, 36 
we still lack an understanding of how LVRs develop and the best approach to prevent and manage 37 
the condition. This review discusses recent insights into the key prognostic factors that influence the 38 
risk of recurrence, focusing on the role of tumour-adjacent non-neoplastic epithelial disorders, 39 
which are thought to play a causative role. 40 
 41 
Main body of text 42 
Background 43 
Vulval cancer comprises only 6% of all gynaecological malignancies reported in the UK, with 44 
squamous cell carcinoma (VSCC) making up 90% of all cases. It is predominantly a disease of the 45 
elderly with three-quarters of cases affecting those aged over 60 years 1. Radical vulvectomy is the 46 
mainstay of treatment for VSCC, with the extent of surgery depending on a number of factors that 47 
include: the size of the tumour; its location and proximity to vital organs; fitness to tolerate major 48 
surgery; FIGO stage; and wishes of the patient. Recurrent disease is common following primary 49 
treatment in VSCC with more than half of the cases recur locally involving the vulvoperineal area 2 3. 50 
The rate of local vulval recurrence (LVR) has not changed over time and affects at least 1 in 4 51 
patients following primary treatment 2 4.  Inadequate surgical excision has always been thought to be 52 
the main reason attributed to the development of LVR, but this belief is increasingly being 53 
challenged by new evidences 5 6. Furthermore, a number of studies have showed that other 54 
clinicopathological factors are equally important in determining the timing, pattern and frequency of 55 
LVR following surgery; in particular, the presence of non-neoplastic but dysplastic epithelium found 56 
adjacent to the primary tumour 7-10. The latter is of particular interest given that more than two-57 
thirds of VSCC cases arise in a background of histologically abnormal or dysplastic epithelium such as 58 
vulval intraepithelial neoplasia (VIN) or Lichen Sclerosus (LS) 11. 59 
Managing LVR can be challenging especially in the elderly population who often have other medical 60 
comorbidities and in those who have previously received extensive surgery or exposure to 61 
radiotherapy. Further surgery is often associated with physical and psychosexual comorbidities and, 62 
in some instances, can result in the loss of urinary and bowel functions. Disappointingly, we still lack 63 
an understanding of how LVRs develop and the best approach to prevent and manage the condition. 64 
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This review discusses recent insights into the key prognostic factors that influence the risk of LVR 65 
and focuses on the role of non-neoplastic epithelial disorders (NNEDs), which are thought to arise 66 
from a field of molecularly altered epithelium termed a “field of cancerization”. 67 
The dual pathobiology of VSCC  68 
Like squamous cell carcinoma of the head and neck (HNSCC), VSCC is known to arise through HPV-69 
dependent and independent routes (see Figure 1). The current disease paradigm holds that 70 
following persistent infection with high-risk (HR)-HPV strains, women are at risk of developing usual 71 
or classical type vulvar intraepithelial neoplasia (uVIN), which subsequently progress into basaloid or 72 
warty type squamous cell carcinoma (SCC) 12 13. It is estimated that 40% of all VSCC cases arise 73 
through the viral-dependent route; interestingly, the prevalence of HR-HPV positive tumours is 20% 74 
higher in the United States compared to the UK 14-19. Most cases of the tumour test positive for 75 
HPV16 and, to a lesser extent, HPV18 and HPV33 20. HPV-associated tumours typically affect younger 76 
women, aged <65 years, and the incidence in this age group is reportedly increasing in the UK and 77 
elsewhere 1. This increase is a reflection of the rising incidence of the precursor lesion, uVIN, in 78 
young women, due in part, to the rise in the prevalence of infection with HR-HPV strains 20. Although 79 
women with uVIN often suffer debilitating physical and psychosexual symptoms, the risk of 80 
progression to VSCC is substantially lower than that of cervical intraepithelial neoplasia; current 81 
estimates of disease progression are less than 10% 21. 82 
The virus independent route is associated with the development of keratinising tumours in a 83 
background of differentiated intraepithelial neoplasia (dVIN) or Lichen Sclerosus (LS) 12 13. It is 84 
thought that the primary trigger of carcinogenesis in this setting is chronic inflammation, which 85 
results in repeated injury, scarring and ultimately, sclerosis of the affected epithelium. The sustained 86 
episodes of cell renewal and repair, which accompanies chronically inflammation, are associated 87 
with DNA damage and a high probably of mutation or silencing of tumour suppressor genes (TSGs), 88 
which, over time can result in oncogenic transformation 22. Nevertheless, it remains unclear if LS 89 
gives rise to dVIN as there is no clear-cut connection between the two conditions. Similarly, it is also 90 
unclear whether dVIN, like uVIN, is a precursor lesion in HPV-negative VSCC. Women within this age 91 
group are usually older (> 65 years) and critically they are also more likely to have other medical co-92 
morbidities, which may pose particular challenges in managing their cancer. 93 
Although the current theory suggests that VSCC may arise through these two distinct pathways, our 94 
recent study has shown that resected tumour specimens from almost a third of patients were found 95 
to have LS, uVIN and dVIN co-existing with each other 7. This finding raises the question as to 96 
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whether the two routes to VSCC development are mutually exclusive. Understanding the underlying 97 
pathobiology which leads to the development of VSCC is crucial as many studies have found that the 98 
presence of NNEDs found adjacent to the primary tumour appears to influence the rate and pattern 99 
of local recurrence 7-10 23 24.  Furthermore, in other HPV-associated cancers, such as HNSCC and anal 100 
cancer, there is compelling evidence to suggest that HPV-positivity confers a survival advantage. 101 
However, despite this clear-cut correlation in these two diseases, studies on VSCC have failed to 102 
demonstrate that HR-HPV positivity is an independent predictor of disease-free survival 19 25-27. The 103 
difficulty in revealing the expected association with HPV status in women with VSCC may flow in part 104 
from the frequency with which uVIN co-exists alongside LS and dVIN, both of which impose an 105 
increased risk of LVR development 7. It is also worth noting that the detection HR-HPV DNA in 106 
tumour specimens does not necessarily indicate the presence of transcriptionally active virus given 107 
that the virus might have undergone integration, become methylated and transcriptionally silent 28. 108 
Alternatively, the presence of HR-HPV DNA might constitute a transient reactivation or new infection 109 
that is not necessarily related to viral-driven oncogenesis 29. Due to the complexity of the HPV life 110 
cycle, the significance of HR-HPV DNA positivity in VSCC remains unclear. Further studies are 111 
required to measure the levels of expression of the HR-HPV oncogenes and its surrogate markers (E7, 112 
p16INK4a and MCM7); these biomarkers would confirm if oncogenesis is driven through the HR-HPV 113 
route. 114 
Topography of VSCC recurrence 115 
Like HNSCC, our recently published study, along with two others, has identified two different 116 
patterns of local recurrence in VSCC (Figure 2). A local vulval recurrence can occur on a site 117 
previously occupied by or distant to the primary tumour 7 8 23. This pattern of local recurrence was 118 
first described in SCC of the oral cavity and upper respiratory tract 30, and, like VSCC, the former can 119 
be derived from both HPV-dependent and HPV-independent routes. Molecular profiling of HNSCC 120 
has identified three distinctive patterns of local recurrence. Tumours that arise on a site previously 121 
occupied by the primary tumour are termed a local relapse (LR), and are thought to be a true local 122 
recurrence, while tumours that occur at least 2cm or more away from the primary tumour are 123 
termed second field tumours (SFT) or second primary tumours (SPT) and are thought to constitute 124 
new tumours that could be genetically related (SFT) or unrelated (SPT) to the primary tumour 31. 125 
Although still speculative, it is thought that both SFT and SPT arise within an area of genetically 126 
altered pre-neoplastic epithelium contiguous with the primary tumour that has a propensity to 127 
undergo malignant transformation 32. 128 
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Unlike HNSCC, a detailed examination of the topography of local recurrences in vulval cancer has not 129 
been adequately described. As such, very few retrospective cohort studies have attempted to 130 
categorise LVR based on the site and time at which the disease recurs following primary surgery. 131 
Bosquet et al. defined “recurrence” as a disease which relapses within five years of treatment while 132 
those that relapse after five years were termed a “re-occurrence” 33. Both Regauer et al. and Oonk et 133 
al. postulated that disease which recurs locally within 3 months of treatment is primarily due to 134 
treatment failure, while van der Velden et al. described a “true” local recurrence as a disease which 135 
recurs within 2cm of or “near” to the excision scar 9 34 35. However, it is important to note that the 136 
definitions of local recurrence used by these authors are purely hypothetical and based on 137 
observational studies and, unlike the case for HNSCC, were not based on molecular profiling.  138 
Clinico-pathological determinants of LVR 139 
Tumour-free pathological margins of 8mm or more, measured after formalin fixation, is considered 140 
to be the gold standard practice to minimise local disease recurrence. The current surgical practice 141 
advocates the removal of at least 15mm of disease-free tissue, lateral and deep margins, so that 142 
after fixation a ≥8mm histological cancer-free margins can be achieved to avoid LVR 36. This 143 
recommendation is based on a study conducted by Heap et al. on a small retrospective cohort 37. 144 
The study found that none of the patients with pathological margins of ≥8mm had recurrent disease, 145 
and local recurrence was only found in those with pathological margins of <8mm.  While a number 146 
of independent studies support these findings 23 38, other more recent studies, which interrogated 147 
pathological margins in addition to other clinical-pathological determinants, dispute the notion that 148 
inadequate excision margin is the sole reason that contributes to LVR 5-7. After an extensive review 149 
of the literature, we have identified 27 independent retrospective cohort studies which have 150 
assessed the clinicopathological factors that determine LVR (see Table 1). Collectively, these studies 151 
found, that in addition to inadequate excision margins, there were other clinical determinants that 152 
influenced the risk of LVR. These included: groin node metastasis; the presence of Lichen Sclerosis 153 
(LS) and vulvar intraepithelial neoplasia (usual and differentiated type VIN) adjacent to the primary 154 
tumour; older age group; tumour size; tumour multifocality; histology grade; lymphovascular 155 
invasion (LVSI); perineural invasion; site of tumour; the type of surgery performed; and others 4-7 9 11 156 
23 33 34 37-52. However, it remains unclear which of the risk factors best predict LVR, as each study 157 
identified different predictors, and none were in total agreement with each other.  158 
The inconsistencies in the findings from each retrospective study can be attributed to a number of 159 
possibilities. Firstly, different methodologies were used in each study to collect and analyse its 160 
results; secondly, the majority of these studies were conducted in a single institution where clinical 161 
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practice in managing VSCC can be substantially different; thirdly, there was a lack of consistency in 162 
the clinical determinants used in each study; fourthly, the definition for LVR varies between each 163 
study and, at times, used interchangeably with distant metastasis; and lastly, there was lack of 164 
consensus in defining what constituted a true LVR. As a result, these studies failed to identify the 165 
common prognostic variable(s) involved in LVR. Taking into the account the limitations of these 166 
studies, we conducted an analysis of our cohort to evaluate all potential clinicopathological 167 
determinants previously implicated in the development of LVR 7. We also dichotomized local 168 
recurrences into LR or SFT/SPT, according to the definitions obtained from molecular studies on 169 
HNSCC. Interestingly, our results showed that more than half of the cases of local recurrence 170 
occurred at a site distant to the primary tumour; we also found that the presence of LS appeared to 171 
be the only clinical determinant that reliably predicts LVR. These patients were not at greater risk of 172 
developing distant metastasis when compared to other clinical determinants evaluated, suggesting 173 
that local disease recurrence probably occurs as a result of the ongoing chronic inflammatory 174 
dermatosis associated with the residual LS. Although we have yet to perform molecular profiling of 175 
the tumour specimens obtained in our study, we believe that LVR (both SFT and SPT) originate from 176 
a “field" of molecularly altered epithelium that has acquired the necessary genetic changes to 177 
undergo malignant change. Contrary to previous beliefs, they do not occur as a result of inadequate 178 
excision margins as described by Heap and colleagues. It is also worth highlighting that Heap et al. 179 
drew their inferences solely from unadjusted estimates, and their findings could be confounded by 180 
other clinicopathological variables that were not evaluated in their study. 181 
Field cancerization and LVR 182 
The concept of field cancerization was first proposed by Slaughter et al. in 1953, who studied the 183 
histology of dysplastic epithelial tissue at tumour-adjacent surgical margins in an attempt to explain 184 
the reason for the development of multiple primary tumours and local recurrence in the oral cavity 185 
and upper respiratory tract 30.  In the original study, histological examinations were performed on 186 
normal tissue at surgical margins adjacent to the tumour. This study revealed the presence of 187 
multiple independent primary lesions and evidence of hyperplastic or atypical epithelium in 188 
seemingly histologically normal tissue contiguous with the primary tumour. Since the development 189 
of molecular biology, the concept of field cancerization has now been redefined in molecular terms. 190 
Mutation or epigenetic silencing of growth promoting or tumour suppressor genes predisposes 191 
epithelium to undergo oncogenic transformation, allowing genetically altered cells to expand and 192 
colonise large areas of the epithelium. This phenomenon partly explains the multifocality of 193 
tumours, as secondary tumours or local recurrences, such as SFT and SPT, emerge some years later 194 
7 
 
after removal of the primary tumour. The multifocality and multicentricity of vulval neoplasia, its 195 
propensity to recur locally but at sites distant from the primary disease, point to this tumour arising 196 
within a field of cancerization in which at least some of the molecular abnormalities present in the 197 
primary tumour will be detected in adjacent histologically normal epithelium.  198 
As more than two-thirds of VSCC arise on a background of atypical skin in the form of uVIN, dVIN, or 199 
LS 11, it is plausible that these non-neoplastic epithelial disorders arise from molecularly altered 200 
epithelium that is generated through virus-dependent and independent routes. As such, NNEDs may 201 
constitute pathological biomarkers which indicate the presence of a molecularly altered field of 202 
epithelium. In the case of uVIN, these lesions are derived from HR-HPV infected epithelium that has 203 
acquired additional molecular changes that have progressed to high-grade VIN. Several studies 204 
performed on HIV-infected women revealed the presence of multifocal HPV-associated warts and 205 
uVIN lesions/condylomata in the genital tract of HIV-positive women pointing to the existence of a 206 
cancer field in these patients 53 54. Using molecular analyses involving X chromosome inactivation, 207 
Rosenthal and colleagues revealed that high-grade VIN lesions contiguous with VSCC were of clonal 208 
origin, raising the possibility that these VSCCs were derived from molecularly altered clones within 209 
the VIN lesions 55. However, the question of whether HR-HPV infection per se generates a cancer 210 
field is currently unclear. Although data for VSCC is unavailable, a recent study performed in HNSCC 211 
has revealed that normal epithelium obtained from resection margins were uniformly HPV negative, 212 
suggesting that at least in this disease, HR-HPV may not generate a field of molecularly altered 213 
epithelium. This finding supports the notion that unlike HPV negative HNSCC, HR-HPV-positive 214 
HNSCC exhibits lower rates of local recurrence 56. 215 
While uVIN is a putative precursor lesion for HPV-positive VSCC, it is still debatable whether LS is a 216 
precursor lesion for the HPV-negative counterpart. Although recent evidence shows that residual LS 217 
that remains after excision of the primary tumour increases the risk of local recurrence 7-9, the 218 
absolute risk of recurrence in these women is not well defined. The notion that LS generates a field 219 
of cancerization, much like that observed in HPV-negative HNSCC, is a strong but as yet unproven 220 
concept. However, such an idea is not without foundation. It is now well established that chronic 221 
inflammation, coupled with sustained episodes of wound-healing, can predispose epithelial tissue to 222 
oncogenic transformation 57. It is still unclear whether inflammation plays a permissive or promoting 223 
function in the generation or expanding “initiated” (i.e. mutated) cells. Chronic inflammation is 224 
associated with abnormal cytokine and growth factor production which can fuel the expansion of 225 
molecularly altered or premalignant cells. A number of studies have shown that LS lesions 226 
overexpress p53 protein and, in a significant proportion of cases, harbour mutated TP53 genes 22 58 227 
8 
 
59. The induction of p53 is most likely associated with a DNA damage response, induced through the 228 
production of reactive oxygen species (ROS) or by ischaemic stress, both of which are produced 229 
during chronic inflammation. Increased levels of ROS are associated with the recruitment of the 230 
epigenetic modulator, DNMT1, to CpG-rich islands upstream of promoters of both growth regulatory 231 
(i.e. p16INK4A) and genes involved in the DNA damage response 60. Chronic or sustained bouts of 232 
inflammation also cause alterations to the underlying stroma, converting normal fibroblasts into 233 
myofibroblasts which produce cytokines, chemokines and growth factors that can promote the 234 
growth of pre-malignant epithelial cells. An overwhelming body of evidence now supports a key role 235 
of the stromal microenvironment in field cancerization and the development of both primary 236 
tumours and local recurrences 60. This is particularly relevant as previous clinical studies which 237 
evaluated the risk of LVR following an en bloc vulvectomy, and a triple incision, showed no 238 
difference in risk despite the removal of less “normal” tissue in the latter 61-64. Therefore, removing 239 
excessive non-neoplastic skin during primary surgery may not have prevented the development of 240 
LVR as the adjacent skin bought together to close the wound may have already undergone a “field 241 
transformation” that may eventually give rise to an LVR.      242 
The challenges in managing local VSCC recurrence 243 
The treatments for LVR have not changed over the last three decades, and surgical excision 244 
continues to be the only treatment modality for cure 2 65.  Surgery, however, may not be suitable for 245 
all patients and the procedures can be challenging especially in those who have previously had wide 246 
radical excision or radiotherapy. Reconstructive surgery is often required following primary excision 247 
to restore anatomy and function, as extensive scarring from previous surgery often reduces tissue 248 
volume and renders its flexibility to achieve primary closure. As a result, a skin flap is often 249 
harvested to cover the defect left after radical surgery. For a tumour which recurs and encroaches 250 
the urethra, anus or vaginal, pelvic exenteration followed by reconstructive surgery may be required 251 
to remove the disease completely if the patient is physically fit enough to undergo the operation. 252 
For those patients who previously had radiotherapy to their vulval, wound breakdown following 253 
subsequent surgery is common because irradiated skin often has an inadequate blood supply and a 254 
slow healing rate, making skin grafting unsuitable for most of them. 255 
Squamous cell carcinomas, in general, are radiosensitive, but several studies have revealed poor 256 
treatment responses for large tumours when used alone without surgery 2. However, radiotherapy 257 
alone has been used successfully to treat low volume disease which recurs in the vulva 66.  The use of 258 
concurrent chemotherapeutic agents such as 5-flurouracil, Mitomycin C and platinum agents with 259 
irradiation have proved effective in managing large volume disease in patients who are radiotherapy 260 
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naïve or in those who are physically unfit for surgery 67. Neoadjuvant chemoradiotherapy followed 261 
by surgery is still superior to chemoradiotherapy alone in treating local recurrences, as overall 262 
survival is significantly better in those who can have surgery 67. Concurrent chemoradiotherapy may 263 
also be used to reduce the tumour volume before surgery, sparing those patients who required an 264 
exenterative surgery from having a simple radical excision; but defunctioning colostomy may be 265 
necessary in cases where the tumour recurs in close proximity to the anorectal canal 2.  266 
Nevertheless, as VSCC mostly affects the elderly population, only a small number of patients are 267 
physically fit enough to endure such forms of aggressive triple therapies that involve chemo-268 
radiation and surgery. As currently chemotherapeutic agents are used as an adjunct to radiotherapy 269 
or surgery and in palliative setting, there is a need to look for new chemotherapeutic drugs that can 270 
be used as a lone therapy for VSCC so that we are less reliant on surgery. 271 
Conclusion 272 
Currently, there is a paucity of knowledge regarding the timing, topography and aetiology of local 273 
VSCC recurrence. The notion that inadequate surgical excision margins are the driver for local 274 
recurrence is increasingly being challenged by studies utilising more sophisticated statistical analysis 275 
to evaluate the clinical determinants which predict LVR.  Based on current evidence, we hypothesise 276 
that LVR arises within a field of molecularly altered epithelium that is generated as a result of 277 
chronic inflammation or infection with oncogenic HPV strains. We suggest that LVRs develop in a 278 
pre-existing field of molecularly altered epithelium from clones that have acquired the necessary 279 
mutations to undergo malignant transformation. Future studies should utilise molecular profiling 280 
techniques to identify the molecular changes present in these pre-cancerous fields so that potential 281 
biomarkers or gene signatures can be determined, and these used to stratify patients into those who 282 
are most likely at risk of developing local recurrences. Unlike HNSCC, the contiguous nature and ease 283 
of accessibility of the vulva made this organ an ideal model to study how the field of cancerization 284 
develops and the key molecular changes that predispose cells within the field to tumour formation. 285 
This analysis would allow us to develop field therapies that could be administered short- or long-286 
term to delay or prevent local VSCC recurrence. In the case of LS-associated VSCC, where chronic 287 
inflammation appears to play a vital role in disease pathology and tumour recurrence, the use of 288 
topical steroids may prevent or delay local recurrences by reducing inflammation and re-establishing 289 
a more ”normal” stromal microenvironment. 290 
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Table 1: Clinico-pathological determinants associated with local VSCC recurrence (LVR) 
*Potential duplication of cohorts; LR – local recurrence, LVR – local vulval recurrence, SFT – second field tumour 
asite of LR not defined; bthe appearance of tumour in a new location after treatment, or in the same location after a minimum disease-free period of 6 months; crecurrence defined as 
'vulva'; dde novo: >3 months after definitive surgery; eLR defined as tumour recur at a site remote from initial tumour; fstatistical analysis of recurrence included distant metastasis; 
grecurrence: development of SCC in a previously treated vulva/groin within 5 years, reoccurrence: development of SCC in vulva/groin after 5 years; hLR: at or near the site of vulvectomy 
scar; iprimary tumor site recurrence (up to and including 2 cm from the vulvectomy scar); jLR: >2cm from vulvectomy scar; k'recurrence' was defined as new appearance of tumour after 
therapy with radical intent, unsure if also encompassed distant recurrence 
 
Author Year Cohort size (n) Location of LVR (n) Determinants associated with LVR 
Yap et al. [7] 2016 201 LVR= 66 episodes, LR= 29 episodes; SFT= 26 episodes LR and SFT: Lichen Sclerosis 
Holthoff et al. [43] 2015 94 LRa recurrence in primary tumour = 31 'recurrent tumour' = 9 Perineural invasion 
Iacoponi et al. [51] 2013 87 LRb= 23 Tumour size 
Larsson et al. [40] 2012 133 LRc= 31 None identified 
Stankevica et al. [41] 2012 107 LRa= 65 Site of primary cancer (midline disease) 
Woelber* et al. [5] 2011 102 LRa= 10 Excision margins not significant 
Regauer [9] 2011 75 LRd= 35 Presence of Lichen Sclerosus adjacent to main tumour 
Sznurkowski et al. [39] 2010 59 LRa=10 Multifocal disease 
Groenen et al. [6] 2010 93 LRa= 18 Excision margins not significant 
Tantipalakorn et al.[8] 2009 121 LR=26 (primaryh=13, remotej=13) Primary recurrence= excision margins<8mm; remote recurrence=  Presence 
of Lichen Sclerosus adjacent to main tumour 
Woelber* et al. [52] 2009 103 LRc= 8  None identified 
Cheng et al. [45] 2009 100 LRa= 20 Lymphovascular invasion, lymph node metastasis 
Eva et al. [11] 2008 200 LRa= 34 (estimated) Presence of dVIN adjacent to main tumour 
Ayhan et al. [44] 2008 91 LRa= 8 Surgery type, lymph node metastasis, advanced stage disease, ulcerative 
lesion, tumour size 
Yoder et al. [50] 2008 78 LRe= 11 Histological grade, incomplete resection, depth of invasion 
Chan et al. [38] 2007 90 LRf= 13 Excision margins, groin node metastasis 
Woolderink et al. [42] 2006 125 LRa= 29 Age  >74 years 
Bosquet et al. [33] 2005 330 LRg= 64 (30= reoccurrence; 34= recurrence) Recurrence: Inguinal nodal metastasis;  Re-occurrence: None identified 
Van der Velden et al. [34] 2004 76 LRh= 15 Triple incision (vs en bloc) 
Rouzier et al. [23] 2002 215 LRi= 13; distant recurrence= 13, Skin bridge recurrence= 7 Depth of invasion, incomplete resection margins 
De Hullu et al. [46] 2002 253 LRa= 18 at 2 years; 32 at 4 years Excision margins <8mm 
Maggino et al. [49] 2000 502 ‘perineal' =94 FIGO stage, lymph node metastasis, Lymphovascular space invasion 
Preti et al. [10] 2000 101 LRa= 18 VIN 2/3, FIGO stage, multifocal disease , lymphovascular space invasion, 
incomplete tumour resection 
Fonseca-Moutinho et al. [4] 2000 56 LRa= 11 at 2 years LRa 15 at 5 years FIGO stage IVa, groin node metastasis 
Look et al. [48] 1993 154 ‘recurrence’k= 25 Lymph node metastasis 
Lingard et al. [47] 1992 90 LRa= 16 Multifocal disease, tumour size (stage), inadequate excision margins 
Heaps et al. [37] 1990 135 LRa= 21 Excision margins <8mm, depth of invasion, tumour thickness, 
lymphovascular space invasion, keratinizing tumour, mitotic activity 
 
